Literature DB >> 29443288

Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essence.

Mark S Freedman1.   

Abstract

Entities:  

Year:  2011        PMID： 29443288      PMCID： PMC5766179          DOI： 10.1212/CPJ.0b013e31823cc2c2

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  7 in total

1.  'Time is brain' also in multiple sclerosis.

Authors:  Mark S Freedman
Journal:  Mult Scler       Date:  2009-10-06       Impact factor: 6.312

2.  Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

Authors:  Bhupendra Khatri; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Ludwig Kappos; Xavier Montalban; Jean Pelletier; Tracy Stites; Stacy Wu; Fred Holdbrook; Lixin Zhang-Auberson; Gordon Francis; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2011-05-13       Impact factor: 44.182

3.  Axonal transection in the lesions of multiple sclerosis.

Authors:  B D Trapp; J Peterson; R M Ransohoff; R Rudick; S Mörk; L Bö
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

4.  Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.

Authors:  Sheila A Doggrell
Journal:  Expert Opin Pharmacother       Date:  2010-07       Impact factor: 3.889

5.  Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.

Authors:  Gavin Giovannoni; Stuart Cook; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Anthony Hamlett; Vissia Viglietta; Steven Greenberg
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

Review 6.  Pathological heterogeneity of idiopathic central nervous system inflammatory demyelinating disorders.

Authors:  C Lucchinetti
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

7.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245
  7 in total
  3 in total

Review 1.  Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.

Authors:  Andrew L Smith; Jeffrey A Cohen; Le H Hua
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero.

Authors:  Andrew L Smith; Jeffrey A Cohen; Daniel Ontaneda; Mary Rensel
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-12-12

3.  Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.

Authors:  Assunta Bianco; Matteo Lucchini; Rocco Totaro; Roberta Fantozzi; Giovanna De Luca; Sonia Di Lemme; Giorgia Presicce; Luana Evangelista; Valeria Di Tommaso; Roberta Pastorino; Chiara De Fino; Valeria De Arcangelis; Diego Centonze; Massimiliano Mirabella
Journal:  Neurotherapeutics       Date:  2021-09-07       Impact factor: 7.620
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.